BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 28343093)

  • 1. Influence of genetic variants of CYP2D6, CYP2C9, CYP2C19 and CYP3A4 on antiepileptic drug metabolism in pediatric patients with refractory epilepsy.
    López-García MA; Feria-Romero IA; Serrano H; Rayo-Mares D; Fagiolino P; Vázquez M; Escamilla-Núñez C; Grijalva I; Escalante-Santiago D; Orozco-Suarez S
    Pharmacol Rep; 2017 Jun; 69(3):504-511. PubMed ID: 28343093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining screening panel of functional variants of CYP1A1, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 genes in Serbian population.
    Skadrić I; Stojković O
    Int J Legal Med; 2020 Mar; 134(2):433-439. PubMed ID: 31858263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.
    Seven M; Batar B; Unal S; Yesil G; Yuksel A; Guven M
    Mol Diagn Ther; 2014 Apr; 18(2):229-36. PubMed ID: 24338437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic relevant polymorphisms of CYP2C9, CYP2C19, CYP2D6, and CYP3A5 in Bhutanese population.
    Dorji PW; Wangchuk S; Boonprasert K; Tarasuk M; Na-Bangchang K
    Drug Metab Pers Ther; 2019 Dec; 34(4):. PubMed ID: 32004143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prediction Algorithm for Drug Response in Patients with Mesial Temporal Lobe Epilepsy Based on Clinical and Genetic Information.
    Silva-Alves MS; Secolin R; Carvalho BS; Yasuda CL; Bilevicius E; Alvim MK; Santos RO; Maurer-Morelli CV; Cendes F; Lopes-Cendes I
    PLoS One; 2017; 12(1):e0169214. PubMed ID: 28052106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VARIANTS OF THE FORMATION AND COURSE OF DRUG-RESISTANT EPILEPSY IN CHILDREN WITH GENETIC POLYMORPHISMS OF CYP2C9, CYP2C19, CYP3A4.
    Tantsura LM; Pylypets OY; Tretiakov DV; Tantsura YO
    Wiad Lek; 2023; 76(5 pt 1):1007-1013. PubMed ID: 37326083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of CYP2C9, CYP2C19, and CYP2D6 Polymorphisms in Allergic Patients with Chemical Sensitivity.
    D'Attis S; Massari S; Mazzei F; Maio D; Vergallo I; Mauro S; Minelli M; Bozzetti MP
    Int Arch Allergy Immunol; 2019; 179(3):173-186. PubMed ID: 30943525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
    Taur SR; Kulkarni NB; Gandhe PP; Thelma BK; Ravat SH; Gogtay NJ; Thatte UM
    J Postgrad Med; 2014; 60(3):265-9. PubMed ID: 25121365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.
    Veiga MI; Asimus S; Ferreira PE; Martins JP; Cavaco I; Ribeiro V; Hai TN; Petzold MG; Björkman A; Ashton M; Gil JP
    Eur J Clin Pharmacol; 2009 Apr; 65(4):355-63. PubMed ID: 18979093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C9 (*2&*3) and CYP2C19 (*2&*3) polymorphisms among children with nonlesional epilepsy: a single-center study.
    Eltalal S; El Ayouty M; El-Said A; Wahba Y
    Acta Neurol Belg; 2021 Dec; 121(6):1623-1631. PubMed ID: 32683556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population.
    Scott SA; Edelmann L; Kornreich R; Erazo M; Desnick RJ
    Pharmacogenomics; 2007 Jul; 8(7):721-30. PubMed ID: 18240905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.
    Fohner A; Muzquiz LI; Austin MA; Gaedigk A; Gordon A; Thornton T; Rieder MJ; Pershouse MA; Putnam EA; Howlett K; Beatty P; Thummel KE; Woodahl EL
    Pharmacogenet Genomics; 2013 Aug; 23(8):403-14. PubMed ID: 23778323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
    Zuo J; Xia D; Jia L; Guo T
    Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population.
    Hahn M; Müller DJ; Roll SC
    Pharmacopsychiatry; 2021 Mar; 54(2):81-89. PubMed ID: 33327018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
    Chamboko CR; Veldman W; Tata RB; Schoeberl B; Tastan Bishop Ö
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between CYP2C9/2C19 polymorphisms and phenytoin maintenance doses in Asian epileptic patients: A systematic review and meta-analysis
.
    Liao K; Liu Y; Ai CZ; Yu X; Li W
    Int J Clin Pharmacol Ther; 2018 Jul; 56(7):337-346. PubMed ID: 29628024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allele frequencies of single nucleotide polymorphisms of clinically important drug-metabolizing enzymes CYP2C9, CYP2C19, and CYP3A4 in a Thai population.
    Sukprasong R; Chuwongwattana S; Koomdee N; Jantararoungtong T; Prommas S; Jinda P; Rachanakul J; Nuntharadthanaphong N; Jongjitsook N; Puangpetch A; Sukasem C
    Sci Rep; 2021 Jun; 11(1):12343. PubMed ID: 34117307
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.